» Articles » PMID: 11556812

Heterologous Expression of Cytochrome P450 2D6 Mutants, Electron Transfer, and Catalysis of Bufuralol Hydroxylation: the Role of Aspartate 301 in Structural Integrity

Overview
Publisher Elsevier
Specialties Biochemistry
Biophysics
Date 2001 Sep 15
PMID 11556812
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Cytochrome P450 (P450) 2D6 is a polymorphic human enzyme involved in the oxidation of >50 drugs, most of which contain a basic nitrogen. In confirmation of previous work by others, substitutions at Asp301 decreased rates of substrate oxidation by P450 2D6. An anionic residue (Asp, Glu) at this position was found to be important in proper protein folding and heme incorporation, and positively charged residues were particularly disruptive in bacterial and also in baculovirus expression systems. Truncation of 20 N-terminal amino acids had no significant effect on catalytic activity except to attenuate P450 2D6 interaction with membranes and NADPH-P450 reductase. The truncation of the N-terminus increased the level of bacterial expression of wild-type P450 2D6 (Asp301) but markedly reduced expression of all codon 301 mutants, including Glu301. Reduction of ferric P450 2D6 by NADPH-P450 reductase was enhanced in the presence of the prototypic substrate bufuralol. Bacterial flavodoxin, an NADPH-P450 reductase homolog, binds tightly to P450 2D6 but is inefficient in electron transfer to the heme. These results collectively indicate that the acidic residue at position 301 in P450 2D6 has a structural role in addition to any in substrate binding and that the N-terminus of P450 2D6 is relatively unimportant to catalytic activity beyond a role in facilitating binding to NADPH-P450 reductase.

Citing Articles

Cytochrome Binds Tightly to Several Human Cytochrome P450 Enzymes.

Kim D, Kim V, Tateishi Y, Guengerich F Drug Metab Dispos. 2021; 49(10):902-909.

PMID: 34330716 PMC: 8626640. DOI: 10.1124/dmd.121.000475.


Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes.

Guengerich F, Wilkey C, Phan T J Biol Chem. 2019; 294(28):10928-10941.

PMID: 31147443 PMC: 6635447. DOI: 10.1074/jbc.RA119.009305.


Rolapitant Is a Reversible Inhibitor of CYP2D6.

Glass S, Leddy S, Orwin M, Miller G, Furge K, Furge L Drug Metab Dispos. 2019; 47(6):567-573.

PMID: 30952677 PMC: 6505376. DOI: 10.1124/dmd.118.085928.


CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.

Glass S, Martell C, Oswalt A, Osorio-Vasquez V, Cho C, Hicks M Drug Metab Dispos. 2018; 46(8):1106-1117.

PMID: 29784728 PMC: 6038030. DOI: 10.1124/dmd.117.079871.


Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug-Metabolizing Enzymes as a Response to Redox Alteration.

Albertolle M, Phan T, Pozzi A, Guengerich F Mol Cell Proteomics. 2018; 17(5):889-900.

PMID: 29374135 PMC: 5930400. DOI: 10.1074/mcp.RA117.000382.